Inclusion Criteria:

1. * Healthy men, or women of non-childbearing potential
2. * Must agree to use an adequate method of contraception
3. * Body mass index (BMI) of 18.0 to 33.0 kg/m2 as measured at screening

Exclusion Criteria:

1. * Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
2. * Significant allergy requiring treatment
3. * History of clinically significant autoimmune, cardiovascular, renal, hepatic, chronic respiratory or GI disease (except cholecystectomy), neurological or psychiatric disorder, illness/infection/hospitalization or surgical procedure within 30 days prior to first dose of study drug or any uncontrolled medical illness as judged by the investigator
4. * Have poor venous access that limits phlebotomy
5. * Evidence of current SARS-CoV-2 infection or exposure to confirmed infection within 10 days prior to the first dose of study drug
6. * Clinically significant abnormal clinical chemistry, hematology or urinalysis
7. * Hepatitis B, Hepatitis C, HIV, TB
8. * Renal impairment
9. * Pregnant or lactating women or men with pregnant or lactating partners
10. * Received any IMP in a clinical research study within 5 half-lives or within 30 days prior to first dose (whichever is longer)
11. * Taking any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g per day acetaminophen and HRT) in the 14 days or 5 half-lives (whichever is longer) before IMP administration
12. * COVID-19 vaccine within 14 days prior to first dose or have a COVID-19 vaccine scheduled between their first dose of IMP and last dose of IMP.
13. * Drug or alcohol abuse in the past 2 years
14. * Regular alcohol consumption in men \>21 units per week and women \>14 units per week (1 unit = 12 oz 1 bottle/can of beer, 1 oz 40% spirit or 5 oz glass of wine)
15. * Positive alcohol urine test at screening or first admission
16. * Current and within the last six months-smokers, e-cigarettes and nicotine replacement users
17. * Donation of blood within 2 months or donation of plasma within 7 days prior to first dose of study medication
18. * Subjects who are, or are immediate family members of, a study site or Sponsor employee